<DOC>
	<DOC>NCT02604784</DOC>
	<brief_summary>Single center, open label, non-randomized, single-arm, repeated single dose study to explore the efficacy, safety, and Overall Response Rate (ORR) of cisplatin, oxaliplatin and doxorubicin when given as a pressurized intraperitoneal chemotherapy (PIPAC) to patients (men and women) with peritoneal carcinomatosis from ovarian, gastric and colorectal cancers and in primary cancers of peritoneum.</brief_summary>
	<brief_title>Study of Efficacy and Safety of Laparoscopic Intra-abdominal Chemotherapy (PIPAC) Performed in Patients With Peritoneal Carcinomatosis From Colorectal, Ovarian, Gastric Cancer and Primary Peritoneal Tumors</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Clinical and pathological confirmation of peritoneal carcinomatosis from gastric, colorectal and ovarian cancers or primary peritoneal tumors. Patients aged between 18 and 78 years. Performance status sec. ECOG â‰¤ 2 Disease progression/relapse after at least one line of previous i.v. standard chemotherapy in gastric cancer and primary peritoneal tumors and two lines in colorectal and ovarian cancers. Patients with peritoneal carcinomatosis from ovarian, gastric and colorectal cancers and primary peritoneal cancers not eligible to cytoreductive surgery +/ HIPEC. Blood and electrolyte counts, liver, renal and cardiopulmonary function parameters within 10% of the normal range. Written informed consent. Tumor mass present on CTscan in order to allow tumor response assessment with RECISTcriteria. Extraabdominal metastatic disease, with the exception of isolated pleural carcinomatosis. Bowel obstruction. Chemotherapy or surgery within the last two weeks prior to enrollment. Severe renal impairment, myelosuppression, severe hepatic impairment, severe myocardial insufficiency, recent myocardial infarction, severe arrhythmias. Immunocompromised patients such as those with an immunosuppressive medication or a known disease of the immune system. Creatinine clearance &lt; 60 ml /min. Pregnancy. Previous treatment reaching the maximum cumulative dose of doxorubicin, daunorubicin, epirubicin, idarubicin and/or other anthracyclines and anthracenediones. Known allergy to cisplatin or other platinumcontaining compounds or to doxorubicin. Patients of both sexes who do not conduct complete abstinence from heterosexual relationships or agree to use an effective clinically acceptable method (with failure rate &lt;1%) during the study and the following 6 months after the last treatment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Pressurized Intra Peritoneal Air-flow Chemotherapy (PIPAC)</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Peritoneal Carcinomatosis</keyword>
</DOC>